Author:
Rawstron A C, ,Fazi C,Agathangelidis A,Villamor N,Letestu R,Nomdedeu J,Palacio C,Stehlikova O,Kreuzer K-A,Liptrot S,O'Brien D,de Tute R M,Marinov I,Hauwel M,Spacek M,Dobber J,Kater A P,Gambell P,Soosapilla A,Lozanski G,Brachtl G,Lin K,Boysen J,Hanson C,Jorgensen J L,Stetler-Stevenson M,Yuan C,Broome H E,Rassenti L,Craig F,Delgado J,Moreno C,Bosch F,Egle A,Doubek M,Pospisilova S,Mulligan S,Westerman D,Sanders C M,Emerson R,Robins H S,Kirsch I,Shanafelt T,Pettitt A,Kipps T J,Wierda W G,Cymbalista F,Hallek M,Hillmen P,Montserrat E,Ghia P
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference31 articles.
1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.
2. Montserrat E . Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol 2005; 23: 2884–2885.
3. Research C for DE and News & Events—Public Workshop on Minimal Residual Disease (MRD) as a Surrogate Endpoint in Chronic Lymphocytic Leukemia (CLL).
http://www.fda.gov/Drugs/NewsEvents/ucm340707.htm
(accessed 2 February 2015).
4. Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/12/WC500179047.pdf
(accessed 3 February 2015).
5. Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980–988.